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Background: Cholangiocarcinomas are primary malignant tumours developing from the 
epithelia of the biliary ducts from the liver to the end of the bile duct in the duodenum. The 
objective of this review was to share our experience of seven well documented with this 
condition out of eleven observations treated at the Lusaka University Teaching Hospital 
(UTH) and point out the impact of palliative surgery played to provide comfortable quality 
survival.  
Methods: This was a ten-year retrospective study all patients operated on at the Lusaka 
University Teaching Hospital with confirmed diagnostic of cholangiocarcinoma. Seven well 
documented cases out of eleven treated were considered for this study. 
 Results: Of the seven patients diagnosed with cholangiocarcinoma, four were males and 
three were females with ages ranging from 57 to 68 years and mean age of 64 years. At the 
time of admission, painless obstructive jaundice, with loss of appetite and loss of weight 
were recorded in 5 of the 7 patients followed by chronic right upper quadrant pain 
(28.56%). Abdomen Ultrasound and CT Scan were performed only in two patients (28.56%) 
and the per trans hepatic cholangiogram in one patient(14.48%). Not any histological 
diagnosis was made pre or intra operatively. The findings and management outcomes are 
described.  
Conclusion: Despite the small number of these tumours (very rare worldwide) but by 
reviewing literature data, authors noted the severity of the condition related to long 
standing jaundice and co-morbidities, confirmed the challenge in diagnosis and 
therapeutic decision making . They encourage reasonable tumour resection and bile 
diversion as able to procure satisfactory survival as they had many twelve-month survivals 
after palliative surgery without free margins as expected in world literature. However they 
continue appealing for more modern medical imaging and histological diagnostic tools in 
their surgical facilities. 
 Key words: Cholangiocarcinoma, Bile ducts, Gall bladder, Bile obstruction, biliary convergence, 
Surgery. 
 Introduction 
Cholangiocarcinomas are malignant tumours of mutated epithelial cells of the biliary ducts from 
the liver to the duodenum1. These cancers of the bile ducts are rare: 1-2 cases/100.000 
inhabitants in the Western world but seem increasing in some circumstances as stated by 
Landis et al2, prevailing in people of 50 to 70 years old3. They always present serious diagnostic 
and treatment challenge since they usually grow slowly and spread gradually and are diagnosed 
in advanced stages2, 4 making the prognosis poor worldwide with a 5-year relative survival 
estimated for intrahepatic bile duct cancer: 15% (localized), 6% (regional), 2% (distant) and for 
extrahepatic bile duct cancer: 50% (localized), 24% (regional), 2% (distant) as stated by 
American cancer society5. The usual chronic shortage of required management tools in 
developing countries enhances this challenge in our settings. The objective of the study was to 
analyze a ten-year experience on bile duct cancer at the Lusaka with regard to the management 
of these tumours and a 12-month postoperative follow-up. 
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Patients and Methods 
This was a ten-year retrospective study from 1/1/2001 to 1/11/2010 at the Lusaka University 
Teaching Hospital (UTH) including all patients undergoing surgery for cholangiocarcinoma. 
Authors served also as participant observers. The Lusaka UTH is the surgical catchment of 
Zambia and the tertiary referral of the country for all major in general and biliary tree cancer in 
particular. A total of eleven  bile duct cancers were retrieved during the study period but only 
seven with well documented record with regard to targeted variables were considered with this 
study taking in account a twelve-month postoperative follow-up. 
The study used a structured questionnaire including age, sex, ABO group, co-morbidities, risk 
factors, main complaints at the time of admission, clinical examinations findings, performed 
investigations and findings, surgical techniques as well as problems encountered in decision 
making, histological diagnosis and the twelve month-follow up with regard to complication and 
mortality. Despite the small number of patients, after data collection, variables were categorized 
among independent and dependent, compiled and presented on tables and diagrams.  
Case Reports 
The findings in the seven cases are summarized in the tables below.  
Table 1. Case 1.  
Features / complaints MB...NG.; F/62Y; DOA: 15/02/01; ABO group:  A+ 
Symptoms Right upper quadrant pain; Loss appetite; Asthenia; Weight loss 
Co-morbidities High Blood pressure; Diabetes milletus/2; ASA:2 
Risk factors Cholecystitis;  Gallstone 
Signs Right upper quadrant tenderness;  Murphy test +; liver enlargement, 
High blood pressure 
Laboratory tests Hb/10,5g/dL; Bilrubin: 20µmol/L; ALP:40iu/L; Fast BS: 18mmol/L; 
HBSAg: negative 
Medical Imaging Plain Xrays: Right lung basal infiltration, Raised rightt diaphragm; 
Enlarged liver 
Per operative findings 
and treatment  
27/2/01: Right Gall bladder tumour evading liver, Perihepatic lymph 
nodes: Extended cholecystectomy to 5th , 6th  liver segmentectomy+ 
clearance+ intraoperative cholangiographie through T tube  
Outcome Clavien 2 complications. Discharge on 11/3/01; last review 12months 
later; WHO score 2 
KEY: Hb: Hemoglobin,  BS: Blood sugar, ALP: Alkaline phosphatise, HBSAg: Hepatitis B serum Antigen. 
Ultra sound. PUD: Peptic ulcer disease. BP: Blood pressure 
Table 2. Case 2 
Particulars and complaints LUK.DAN ; M/57Y ; DOA 05/09/02.  ABO group: B+ 
Symptoms Painless jaundice; Loss appetite; Asthenia; Weight loss 
Co-morbidities Drinker 20 years; Smoker 15 years;  ASA: 3 
Risk factors Hepatitis B; Liver cirrhosis 
Signs Deep jaundice; Enlarged liver; Right hypochodrium mass; Murphy test+ 
Laboratory tests Hb/9,5g/dL. Bilrubin: 600µmol/L ALP:70iu/L;  HBSAg: positive 
Medical Imaging done Plain Xrays/ non specific infiltration of lungs, US:  enlarged liver, dilated 
common bile ducts 
Per operative findings and 
treatment  
19/10/02: Exploratory laparatomy; Cholecystectomy+ clearance+ 
Ttube + Intra-operative cholangiogram; Intrahepatic peripheral  and 
peri hepaticpedicle biopy: cholangiocarcinoma  
Outcome Clavien 2 Complications;  Discharged on 11th November 2002;  Last 
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Table 3. Case 3. 
Particulars and complaints CHI...PAT; F/64Y; DOA 17/07/04. ABO group: A+  
Symptoms Puritis before Painless jaundice; Asthenia; Loss of appetite; Weight loss   
Co-morbidities Diabetes mellitus type 2; HBP ; Atenolol Alcohol (occasionally.); ASA: 3 
Risk factors Gall bladder stones (previous cholecystectomy) 
Signs Deep jaundice; Enlarged liver; Murphy test negative; BP: 160/90+ 
Laboratory tests Hb/10,5g/dL; Bilrubin: 80µmol/L; ALP:90iu/L;  FastBS 12mmol/L;  
Medical Imaging done US: Very dilated intra hepatic ducts. Transhepaticcholangio+++:  
dilatation of left and right intra hepatic ducts, not visualization beyond 
Per operative findings and 
treatment  
17/08/04: Thoracolaparotomy:  Klatskin tumour; Hepaticojejunostomy 
(Y-loop end to side + biopsies) 
Outcome Clavien 2 Com-plications: bile leak+sepsis.  Discharged on8 th//9/04   




Table 4.Case  4.  
Particulars and complaints NK..CHA ; M/66Y ; DOA 11/06/05.  ABO group: B+ 
 Symptoms Painless jaundice; Puritis before; Loss of appetite; Asthenia; Weight loss 
Co-morbidities High blood pressure 15 years;  Alcohol occasionally; ASA2 
Risk factors PUD on triple therapy for 6 years 
Signs Deep jaundice; Enlarged liver; Distended gall bladder, Murphy test 
positive; BP: 150/95+ Pulse rate 110 
Laboratory tests Hb/11g/dL. Bilrubin: 95µmol/L ALP:92iu/L; Blood culture: Kebsiella; 
AgHBS: negative 
Imaging done US:  enlarged liver,  acalculous gall bladder., Dilated bile duct from 
suprapancreatic area segment:  Transhepatic cholangiogram 
informative+++:  
Per operative findings and 
treatment  
17/07/05: Exploratory laparotomy;  Tumour excision +Choledoco-
jejunostomy (Y loop end to side + biopsies); 4 units blood; Abdominal 
drain 
Outcome Clavien 1 Complications: Discharged on 3/8/05         Last new 12 month 
after discharge: WHO score 2 ; 
 
Table 5. Case  5.  
Particulars and 
complaints 
SE MUN ; M/65Y; DOA 27/07/07. ABO group: B+ 
 Symptoms Painless jaundice; Puritis before; Asthenia; Loss of appetite; Weight loss 
Co-morbidities HBP for 8 years Alcohol (occasionally.) ASA3 
Risk factors Ulcerative colitis 6 years 
Signs Deep jaundice; Enlarged liver; Distended gall bladder, Murphy test positive; 
BP: 140/95+  
Laboratory tests Hb/10g/dL. Bilrubin: 90µmol/;L ALP:96iu/L; AgHBS: negative;  
Medical Imaging done US: enlarged, hetergenous liver, acalculous gall bladder; dilated 
suprapancreatic and  intrahepatic ducts.  CT Scan.informative+++  
Per operative findings 
and 
treatment  
15/8/2007: Exploratory laparotomy; findings: retropanceratic bile duct mass;   
Cholecysto-jejunostomy (Y loop end to side + biopsies);  4 units blood; 
Abdominal drain; biopsy 
Outcome Clavien 1 Complications: Discharged on 25TH August 2007         Last new 12 
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Table 6. Case  6 .        
Particulars and 
complaints 
ND..SHI ; F/65Y ; DOA 25/11/09 ; ABO group: A+ 
Symptoms Right hypochondrium pain; Asthenia; Loss of appetite 
Co-morbidities High Blood Pressure; Duodenal PUD;  ASA: 2 
Risk factors Right  hypochondrium chronic pain: cholecystitis,  gallstone 
Signs Right hypo-chondrium tenderness, Murphy test positive; Right upper 
quadrant mass, Raised blood pressure 
Laboratory tests Hb/10,5g/dL. Bilrubin: N ALP N Fast BS: 8mmol/L; 




27/2/01:: Exploratory  laparotomy: Tumoral gall bladder with stones. 
Cholecystectomy. Intraoperative cholangiogram. Histology: 
Adenocarcinoma of Gall Bladder 
Outcome Clavien 1 complications.; Discharge after 1 week; Last review  WHO 
score 1 
 
Table 7. Case 7. 
Particulars and 
complaints 
BA. FU; M/68Y; DOA: 22/4/10 /04/10. ABO group: O+ 
Symptoms Painless Jaundice 2/12;Puritis before; Asthenia Loss of appetite; Weight 
loss 
Co-morbidities HBP,  Alcohol  ASA3 
Risk factors Ulcerative colitis 6 years 
Signs Deep jaundice; Enlarged liver; Distended gall bladder, Murphy test 
positive 
Laboratory tests Hb/9g/ dL. Bilrubin: 100µmol/L ; ALP:98iu/L; AgHBS: negative. 
Imaging done US: enlarged hetergenous liver, acalculous gall bladder; dilated supra 




17TH May 2010: Exploratory lap; findings; Retro pancreatic bile duct 
mass; Cholecysto-jejunostomy (Y loop end to side + biopsies);  4 units 
blood; Abdominal drain; biopsy 
Outcome Clavien 1 Complications: Discharged after 10 days.  Last new 3 month 
after discharge:WHO score 3. Death 5 months post discharge 
 
There were seven patients: four males (57.1%) and three females (42.9) with ages ranging from 
57 to 68 years and mean age of 63.95 years. Males to Females ratio was of 4/3: 1.33. The 
patients’ ABO groups ranged as follows: 3 A+ (42.9%), 3 B+ (42.9%) and 1 O+ (14.3%). At the 
time of the admission the prominent symptoms were: painless obstructive jaundice, with loss of 
appetite with or without pruritis in five patients (71.4%), followed by chronic right upper 
quadrant pain (28.6%). 
All seven patients have co-morbidities (100%) with ASA classified at ASA3 for four patients 
(57.1%), ASA2 for three patients (42.9%); high blood pressure in six patients (85.71%); alcohol 
abuse in three patients (42.9%); diabetes mellitus in two (28.6%) and tobacco abuse in one 
(14.3%) 
At least one risk factor of developing a cholangiocarcinoma was found in each patient (100%); 
history of gall stone or cholecystitis or cholecystectomy in three patients (42.86%); peptic ulcer 
disease in two (28.86%); liver cirrhosis in one (14.28%), hepatitis B in one (14.28%) and 
ulcerative colitis in one (14.3%) 
The main physical signs were included deep jaundice (71.4%), enlarged liver (85.71%), right 
upper quadrant tenderness (42.9%), right upper quadrant mass (42.9%), high blood pressure at 
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the time of admission (85.7%). Liver function tests confirmed the obstructive (71.4%) with 
raised conjugated bilirubin and alkaline phoshatase. Six patients (85.7%) had an haemoglobin 
rate lower than the normal. Only in three cases (42.9%) out of seven the real location of the 
tumour had been estimated by pre-operative medical imaging: transhepatic cholangiogram 
(third observation), Ultrasonography and CT Scan (fifth and 7th observations). Almost for all the 
seven cases (100%) the precise location was made during the operation with or without 
intraoperative cholangiogram that served also in checking the quality of the repair.  
 
Figure 1. Transhepatic cholangiogram: 
hilar tumour without extension 
 Figure 2. Transhepatic cholangigram: 




Figure 4. US: Low density liver 
metastases 
Figure 5. CTscan Tumour Head of 
Pancreas 
   
Figure  3 . Intra-operative cholangiogram: Slightly 
dilated bile duct. Absence of bile leak 
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Figure 8. Cholangiocarcinoma: 
 papillar type 
Figure 9. Bile duct carcinoma, 
mucine type 
 
The intraoperative findings, procedures of treatment and outcomes are summarized in Table 8  
Apart from one from the gall bladder tumour discovered on the piece of cholecystecomy done 
for cholecystitis, the six other cases were considered as advanced tumours with macroscopically 
distant deposit and performed surgery was assumed palliative. Palliative surgery and 12- 
month follow-up for the various tumours stood as follows: four patients were still alive on the 
12th month review (longer survival than that from literature): one after an extended 
cholecystectomy for gall bladder cancer, a second after post cholecystectomy for gallbladder 
stone and tumour, a third after convergence tumour excision and hepaticojenostomy, a fourth 
after partial supra pancreatic bile tumour excision and choledoco-jejunostomy for an infra hilar 
and pre pancreatic biliary tumour and the fift after a cholecysto jejunostomy for retro-
pancreatic bile duct tumour.  
The death occurred in two other cases: three months after an exploratory laparotomy with 
biopsy of bilateral intrahepatic cholangiocarcinoma and the last after cholecysto-jejunostomy 





Figure 6. Well differentiated 
Cholangiocarcinoma 
 (gall bladder) Observation 1 
Figure 7. Poorly differentiated 
cholangiocarcinoma 
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Discussion 
Topographical Groups  
Cholangiocarcinoma is a primary tumour arising from the biliary duct and not a metastatic 
deposit of another cancer or regional tumour evading or compressing biliary duct. Launois B et 
al6 and Balladur et al7 describe these tumours as extrahépatic tumours or extrabiliary ducts 
cancers and consider separately gallbladder cancers. As these tumours etymologically arise 
from  an epithelial surface of duct (angio) containing bile (chole) we are of the opinion of calling 
all these tumors cholangiocarcinoma wherever  biliary trees are found: in the liver (liver ducts) 
and in the gallbladder (cystic duct). Cholangiocarcinomas then represent a second group of 
primary biliary cancers beside the hepatocellular carcinoma arising from liver cells.   
Based on the location, five types are described4, 8. These include:  
1. Intra-hepatic peripheral cholangiocarcinoma: it may be uni or bilateral located in liver 
parenchyma but not involving the hilus;  
2. Cholangiocarcinoma of the hilus (also called Klastkin tumour or tumour of the proximal 
third of the extra-hepatic biliary duct, most frequent location cholangiocarcinomas);  
3. Middle third extra biliairy duct cholangiocarcinoma is a tumour of the segment of the 
bile duct between the cystic duct junction and the superior border of the pancreas and  
4. Retro- or intra-pancreatic bile duct cholangiocarcinoma arises from the retropancreatic 
portion of the bile duct and its clinical diagnosis with the cancer of the pancreas is not 
easy and the cholangiocarcinoma of gall bladder.  
With regard to hilar or Klatskin tumours (proximal third), Bismuth9  and Bismuth et al10 have 
described 4 types :  
1. Main convergence free,  
2. Main convergence interrupted ,  
3.  Main convergence interrupted + interruption of one secondary convergence ;     
4.  Interrupted major convergence and two secondary convergences   
Another classification, MSKCC, the Type I is involvement of the convergence with or without 
unilateral extension  
Our report is composed of one peripheral intrahepatic case (Case 2); one  hilar case (a 
cholangiocarcinoma type MSKCC 1 without extension in case 3; one  patient with an infra-hilar 
and supra pancreatic tumour in case 4); two retropancreatic cholangiocarcinomas (cases 5 and 
7) and two  gall bladder cholangiocarcinomas      (Cases 1 and 6).  
Frequency and Prognosis 
In our study, the 7 documented cases were seen during a period of 10 years out of 684 digestive 
cancers diagnosed during the same period throughout all five units of visceral surgery. This 
gives a rate of less than one case per year and less than 1% digestive cancers. There were 4 
males and 3 females. Four only were reviewed after one year postoperatively. 
 In worldwide literature, cholangiocarcinoma seems also a rare condition representing 1% of 
digestive system cancers and most prevalent in people ages 50 to 70, as observed by Balladur et 
al7, Anderson et all4 and Kim et al8. However, Patel11 noted that mortality from biliary tract 
malignancy was rising last decades and considered the condition incurable and rapidly lethal 
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unless both primary and possible metastases can fully excised.  All these authors currently, the 
main objective is to obtain a margin negative resection in selected patient for expecting a 
survival of more than 12 months.  Our survival of more than 12 months without margins free  or 
after simple bile diversion encourage  for palliative surgery  
Pathogenesis and Risk Factors 
As for other malignant tumours, aetiology of biliary duct cancers is unknown. However, factors 
able to facilitate the development are known as well as the major co-morbidities.  Gallstones 
were found in three of our patients (Cases 1, 3 and 6). There was also history of peptic ulcer 
disease in two patients (Cases 4 and 6) and of ulcerative colitis in two others (cases 5 and 7). 
One patient had liver cirrhosis (Case 2). As co-morbidities we found in our patients mainly: high 
BP, diabetes mellitus; chronic alcoholism and smoking.  
The most cited factors by Balladur et al7, Anderson et all4 and Kim et al8 were   sclerosing 
cholangitis, bowel chronic inflammatory disease, biliary ducts papillomatosis, Caroli’s disease, 
biliary ducts congenital cysts, cholecystolithiasis and cirrhosis. Leone et al12 have advocated the 
role an epidermal growth factor receptor might place. Kim et al8 have emphasized on the place 
of immune suppressive networks.  
Macroscopically cholangiocarcinoma appears as a nodular or sclerosing lesion and rarely as a 
papillary tumour. The histological type is usually a well differentiated adenocarcinoma 
(Balladur7, Anderson et al4 and Mayo Foundation3). More of our cases were nodular and the 
histology type well differentiated. We had also some poorly differentiated cases.  
Clinical presentation Clinical presentation Clinical presentation depends on the location and the 
stage of the tumour. Asymptomatic type may be found in liver and in the gall bladder. The 
diagnosis will be in this case a result of histology of liver biopsy done for another reason  or on a 
specimen of cholecystectomy performed  e.g. for cholecystitis.  
A gall blabber cancer is generally suspected before complaint of long standing right 
hypochondrium pain in an old patient (mainly a woman). The clinical diagnosis is based on right 
hypochondrium mass indistinctive from the liver. The jaundice that may occur in advanced gall 
bladder cancer is secondary to either extra-hepatic biliary duct (tumour or adenopathies) or to 
the liver evasion by the tumour. Ultrasonography followed or not by CT scan may confirm 
clinical impression [ Balladur P (7); Anderson CD et al (4), Slattery JM (13), and  Mayo 
Foundation (3). The preoperative histology may be obtained on ultrasound or CTscan guided 
percutanous biopsy[Tomkins RK (14) and Mayo Foundation(3)]. In our case n01, the lack of 
above mentioned diagnostic methods, we could only rely on clinical experience with some 
indirect signs from chest and abdominal X-rays. Being the lack of frozen section, the histology 
result was known one month after operation. The case N06 was likely a good case discovered as 
cholecystitis on stone without liver evasion. 
Peripheral intra-hepatic symptomatic cholangiocarcinoma is usually diagnosed later[Tomkins 
RK (13) and Mayo Foundation(3)]. In the beginning, symptoms and clinical signs are those of 
the hepatocellular carcinoma and based on enlarged liver. This hepatomegaly is of variable size, 
nodular, hard, tender with ascitis of rapid growth. Sooner than in hepatocellular carcinoma 
occurs obstructive cholestasis The jaundice may follow obstruction of intrahepatic ducts or 
compression of extra-hepatic ducts by peropedicular lymphadenopathies as in our case n02. 
Biological and morphological investigations are necessary to confirm the diagnosis. For the 
same tumour volume, the obstructive cholestasis is higher in choloangiocarcinoma than in 
hepatocellular carcinoma (total Bilirubin with predominant of conjugated Bilirubin; Alkaline 
phosphatases). The AFP in contrary is higher in hepato-cellular carcinoma than in 
cholangiocarcinoma. The embryonic carcino antigen (ECA) is less specific than the AFP. The 
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morphological investigations are very useful to analyse the impact of tumour on the liver, the 
biliary and portal ducts. They are done mainly by ultrasound, CT Scan and IRM 
In our observation N02, the diagnosis was done on liver and pedicle lymphatic biopsies 
performed during an exploratory laparotomy carried out for obstructive jaundice mainly caused 
by per pedicle lymphadenopaties. The only pre-operative morphphological investigations 
available were chest and plain abdominal X-rays and ultrasound. This latter showing dilated bile 
duct justified the laparotomy that allowed performing liver biopsies of nodular hepatic lesions. 
Extra-hepatic choloangiocarcinoma, from the hilus to the duodenum, presents a similar clinical 
feature of a painless, gradually increasing and apyretic  obstructive jaundice. It is generally 
preceded one or two months before by a diffuse pruritis. It is accompanied with alteration of 
patient’s general condition: loss of appetite and loss of weight. During the evolution, biliary 
sepsis (angiocholitis) may add to the picture abdomen pain, fever and shillings. Physical 
examination notes scratching lesions and may confirm Courvoisier’s law if the tumour is beyond 
the cystic duct junction.  
Biological findings are those of the surgical jaundice (bile retention): increase of alkaline 
phosphatases, gamma GT, bilirubin (conjugated bilirubin). Markers dosages (like ECA and AFP) 
are often negative. 
Ultrasounds, CT scan and IRM confirm the existence of neoplasic obstructive jaundice as noted 
by Balladur P et al (7), Anderson CD et al (4),Slaterry JM (13) and Mayo Foundation (3):  
enlarged liver, dilatation of extra and intra-hepatic ducts. These three investigations may 
indicate the nature of the obstruction and possible hepatic metastatic or primary tumours. 
However better description of the biliary tree lesions are given by biliary ducts contrast study 
carried out during the jaundice by two special investigations: the percutaneous transhepatic 
cholangiogram (PCTHC) and the endoscopic retrograde pancreato-cholangiogram (ERPC). The 
PCTHC shows the upper site of the obstacle and the ERPC its lower configuration.  
In our study, the ERPC could not be performed. Only the PCTHC was done in observations n0 3 
and 4 and allowed to diagnose a Katskin tumour and an infra hilar and supra pancreatic mass. In 
observation n03, because the hilus was obstructed right and left catheterisation was necessary. 
To minimise its complication, it was performed the day of the operation, preoperatively. We 
must mention also the role plaid by intra-operative cholangiogram in our study. Coelio-
mesenteric angiogram, endoscopic ultrasound, Doppler, IRM, SPEC were not available at the 
time of the study as well as the frozen sections during surgery.   In the liver, it is necessary to 
rule out benign conditions like biliary adenoma, biliary cystadenoma, parenchyma harmatomas 
and connectine liver tumours. A biliary adenoma or benign cholangioma is rare and almost 
always benign and might be taken as a liver metastase. It is generally of small size. A biliary 
cystadenoma is also very rare. It is big size and grows slowly and frequently multiloculated on 
ultrasound and CT scan. The surgical treatment is advocated because it is hardly distinguishable 
with a cystadenocarcinoma. A parenchyma hamartoma is also a rare condition but big size, 
multicystic and lobulated in children or in young adult. The treatment is usually surgical 
excision. Connective liver masses may also be observed as hemangio-endothelioma, generalized 
lymphagiomatosis, lipoma, angiolipoma as observed at the CHRU Pontchaillon. 
Principles of Treatment 
More than half of our references are reporting various therapeutic methods dedicated to the 
treatment of cholangiocarcinoma. Evander A et al15 evaluated the results from aggressive 
surgery. Imai K et al16  compared surgery of intrahepatic cholangiocrcinomas. Kaiser et al17 
compared liver resection to transplantation in klastin tumor. The treatment in fact remains 
essentially surgical like in our cases. Other methods  mentioned in literature include radiation 
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therapy, experimental therapy and photodynamic therapy3, 4, 7, 18. The treatment varies with the 
location and the size of the tumor and how it grows and spreads.  
 
Radiation therapy uses of high-energy X-rays to kill cancer cells and shrink tumors as neo-
adjuvant (before surgery) or adjuvant (after surgery) using either external-Beam Radiation 
Therapy (tele-radiotherapy) or internal Radiation Therapy (brachytherapy or curietherapy) 
using radioisotopes put into the area where the cancer cells are found through thin plastic 
tubes: brachy-radiotherapy). At the moment, there is no formal proof of radiotherapy 
effectiveness in increasing the survival duration or avoiding recurrences as noted by Buskirk et 
all19, Grove et al20, Balladur7, Anderson et al4, and Mayo clinic Foundation3.  
 
Experimental Therapy has been cited by many authors4, 21, 22, 23.  Many types of drugs are being 
studied in clinical trials chemotherapy of cholangiocarcinoma, including e.g. docetaxed and 
topotecan and biological therapy or increase of immune system therapy. Photodynamic 
Therapy4 is still another type experimental therapy using  a specific type of light and 
photosensitizing agent to kill cancer cells. Cholangiocarcinoma sensitivity to chemotherapie is 
very low. However, combination of 5-FU and cisplatine has revealed useful in some cases. The 
combination between radiotherapy-chemotherapy need some prospective study.  
Surgery offers the best mode of treatment3, 4. Unfortunately the majority of patients present 
with an unresecable tumour. So many options exist.  
If the cancer is small and has not spread beyond the bile duct, the whole bile duct and the 
tumour are excised a new duct is made by connecting the duct openings to the intestine. Lymph 
nodes also are cleared and examined under the microscope (frozen sections). A 
cholangiocarcinoma of the gall bladder needs extended cholecystectomy (including peri 
pedicular lymph nodes clearance with appropriate liver segmentectomy if hepatic involvement 
as in our case 1.  An isolated peripheral intrahepatic tumour without spread out the liver 
justifies a right or a left hepatectomy with lymph nodes clearance.  
Many surgical procedures have been described for proximal third carcinoma 6, 10, 24,25,.   An 
isolated middle third extrahepatic cholangiocarcinoma like in our case 4 and tumour excision 
and pedicular clearance with choledocojejunostomy. Rarely a retropancreatic tumour will lead 
to a cephalic duodenopancreatectomy with lymphe nodes clearance followed by the connection 
of the bile duct, stomach and pancreatic duct to a Y jejunum loop (Whipple-like procedure) . 
Total hepatectomy and graft is an option for tumours confined in the liver and cannot be 
removed right or left hepatectomy (without distant metastases), as noted by Balladur et al7.  
If the cancer has spread and cannot completely be removed and patient able to undergo surgery, 
palliative surgery is performed to relieve bile retention symptoms. This is done in some hilar 
tumours with free segment of right and left hepatic ducts and all infrahilar advanced 
cholangiocarcinomas. In our case 3, it was performed a bilateral hepatico-jejunostomy for type 
MCCK hilar tumour and in our case 5 a simple cholecystojejustomy was carried out for advanced 
retropancreatic tumour with liver metastases. In some advanced bile duct tumours with free 
hilum: some authors had performed as palliative surgery a direct liver-intestine diversion called 
hepatojejunostomy or hepato-entorostomy intrahepatic cholangio-jejunostomy or intrahepatic 
cholangio-enterostomy9. 27, 28. There exist in these operated cases for palliative surgery, some 
indications of use tubes left in situ or coming outside the body and very uncomfortable 
(transtumoral drainage or intubation). If stents are available and mainly if the patients are weak 
with no hope to cure them, percutaneous transhepatic cholangiography (PTC) and endoscopic 
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retrograde cholangiopancreatography (ERCP) can be used to place plastic or metal stents, which 
help to relieve obstructions. The simple drainage of bile might be undertaken as to prepare the 
operation or as a palliative treatment while nothing else can be done for all advanced hilar or 
infra liver obstruction. A preoperative drainage as noted by Mc Pherson et al29 and Terblanche 
et al30 may also be helpful.  
Conclusion 
Cholangiocarcinoma presents a real diagnostic and treatment challenge worldwide.  These 
difficulties become crucial in developing countries where the chronic shortage of managerial 
tools does not allow an accurate diagnostic preoperatively for planning for a complex 
therapeutic procedure consisting on margins free resection of tumour and bile duct with 
appropriate bile diversion. 
However surgeon’s clinical and therapeutic experience play a real role in offering some hope to 
these patients: with correctly performed surgical procedures for bile diversion, since other 
therapeutic means are still to consider as clinical trials. Five 12-month survivals reported in 
study (more than expected in worldwide literature) by reasonable resection with bile diversion 
without free margins are encouraging in this way. Authors still appeal for more modern medical 
imaging and histological tools in their settings.  
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